The world is moving towards production methods for human biomaterials that are Animal Component Free “ACF” to minimize known bacterial safety risks.

MNPHARM’s production method using plants over traditional methods, is the only method available today that is animal component free “ACF” with human-like glycosylation.

Our proteins  have minimal known bacterial safety risks and include needed human-like glycosylation.

After years of research and development, MNPHARM is positioned for growth and commercial opportunity